Abstract: Markers of acute myeloid leukemia stem cells (AMLSC) are identified. The markers are differentially expressed in comparison with normal counterpart cells, and are useful as diagnostic and therapeutic targets.

Abstract: Processes and materials to detect cancer, transplant rejection, or fetal genetic abnormalities from a biopsy are described. In some cases, nucleic acid molecules, such as cell-free nucleic acids, can be sequenced, and the sequencing result can be utilized to detect sequences indicative of a neoplasm, transplant rejection, or fetal genetic abnormality. Detection of somatic variants occurring in phase and/or insertions and deletions (indels) can indicate the presence of cancer, transplant rejection, or fetal genetic abnormalities in a diagnostic scan, and a clinical intervention can be performed.

Abstract: Engineered proteins, polynucleotides encoding such proteins, and methods of use thereof are provided, which engineered proteins enhance the sensitivity of a cell to IL-2.

Abstract: Methods are provided for treating a subject with for an intracellular pathogen infection, by administering an agent that reduces the binding of CD47 on a infected cell to SIRP? on a host phagocytic cell, in an effective dose for increasing the phagocytosis of infected cells.

Abstract: Systems and methods for seizure detection in accordance with embodiments of the invention are illustrated. One embodiment includes an automated seizure treatment system, including an electroencephalogram (EEG) device configured to record neural activity from a brain of a patient, a treatment device, a processor, and a memory, the memory containing a seizure detection application that configures the processor to obtain an EEG signal from the EEG device, calculate an inverse compression ratio based on the EEG signal, and when the inverse compression ratio is greater than a classification threshold, deliver treatment capable of stopping the seizure to the patient using the treatment device.

Abstract: Embodiments of the invention are generally directed to lignin-modifying enzymes and systems and methods of their manufacture. In many embodiments, yeast strains, including S. cerevisiae, are used to produce and secrete lignin-modifying enzymes Further embodiments are directed to methods to screening peroxidase-producing yeast strains, including S. cerevisiae. Additional embodiments are directed to an expression vector or cassette encoding for a protein of interest and one or more proteins to allow for surface to display of the protein of interest.

Abstract: Systems and methods for generating ligand compound structures are provided. A trained computational framework can utilize an initial core ligand compound structure to generate a ligand compound structure by iteratively adding atomic structures. At each iterative step, the computational framework can select a location for adding an atomic structure and can further select which atomic structure is to be added the selected location.

Abstract: A method is disclosed for generating pixel risk maps for diagnostic image reconstruction. The method produces uncertainty/variance maps by feeding into a trained encoder a short-scan image acquired from a medical imaging scan to generate latent code statistics including the mean ?y and variance ?y; selecting random samples based on the latent code statistics, z˜N(?y,?y2); feeding the random samples into a trained decoder to generate a pool of reconstructed images; and calculating, for each pixel of the pool of reconstructed images, the pixel mean and variance statistics across the pool of reconstructed images. The risk of each pixel may be calculated using the Stein's Unbiased Risk Estimator on the input density compensated data, that involves calculating the end-to-end divergence of the deep neural network.

Abstract: The present invention concerns the enhancement of the osteogenic potential of bone graft by ex vivo treatment with a Wnt polypeptide, such as a liposomal Wnt polypeptide.

Abstract: Implantable devices and/or sensors can be wirelessly powered by controlling and propagating electromagnetic waves in a patient's tissue. Such implantable devices/sensors can be implanted at target locations in a patient, to stimulate areas such as the heart, brain, spinal cord, or muscle tissue, and/or to sense biological, physiological, chemical attributes of the blood, tissue, and other patient parameters. The propagating electromagnetic waves can be generated with sub-wavelength structures configured to manipulate evanescent fields outside of tissue to generate the propagating waves inside the tissue. Methods of use are also described.

Abstract: The present invention relates to a system and method for efficiently modifying the genome of cells to treat diseases via sequential homologous recombination using CRISPR/Cas-mediated genome editing with donor DNA delivered by two or more adeno-associated virus (AAV) vectors.

Abstract: Markers of acute myeloid leukemia stem cells (AMLSC) are identified. The markers are differentially expressed in comparison with normal counterpart cells, and are useful as diagnostic and therapeutic targets.

Abstract: Methods of detecting diagnostic biomarkers on cancer-derived extracellular vesicles such as exosomes by mid-infrared spectroscopy are provided. In particular, methods of detecting ovarian cancer by spectral fingerprint analysis of molecular vibrational spectroscopic markers on individual or subpopulations of extracellular vesicles are disclosed.

Abstract: Systems and methods for tracking objects are disclosed herein. In one embodiment, a system having a processor merges features of detected objects extracted from a point cloud and a corresponding image to generate fused features for the detected objects, generates a learned distance metric for the detected objects using the fused features, determines matched detected objects and unmatched detected objects, applies prior tracking identifiers of the detected objects at the prior time to the matched detected objects, determines a confidence score for the fused features of the unmatched detected objects, and applies new tracking identifiers to the unmatched detected objects based on the confidence score.

Abstract: A stimulation system stimulates anatomical targets in a patient for treatment of dry eye. The system may include a controller and a microstimulator. The controller may be implemented externally to or internally within the microstimulator. The components of the controller and microstimulator may be implemented in a single unit or in separate devices. When implemented separately, the controller and microstimulator may communicate wirelessly or via a wired connection. The microstimulator may generate pulses from a controller signal and apply the signal via one or more electrodes to an anatomical target. The microstimulator may not have any intelligence or logic to shape or modify a signal. The microstimulator may be a passive device configured to generate a pulse based on a signal received from the controller. The microstimulator may shape or modify a signal. Waveforms having different frequency, amplitude and period characteristics may stimulate different anatomical targets in a patient.

Abstract: The present disclosure provides systems, compositions and methods for regulating expression of a target polynucleotide in a cell. The systems, compositions and methods comprise a chimeric receptor polypeptide comprising a G-protein coupled receptor (GPCR) or a fragment thereof, a chimeric adaptor polypeptide, at least one actuator moiety and a cleavage moiety.

Abstract: Compounds, compositions and methods are provided for the inhibition of GBP1. The subject inhibitor compounds can act by inhibiting GBP1 alone and/or GBP1: pro-survival kinase (e.g. serine/threonine-protein kinase pim-1 (PIM1)) interactions. Aspects of the subject methods include contacting a cellular sample with a GBP 1 inhibitor to inhibit the GBP 1 alone and/or GBP 1: PIM 1 interactions. Also provided are compositions and methods for treating cancer. In certain cases the cancer is resistant towards chemotherapy and radiation therapy.

Abstract: Systems and methods for automated identification of STEMI in accordance with embodiments of the invention are illustrated. One embodiment includes a predictive electronic health record (EHR) system, including a processor, and a memory, the memory containing an EHR management application which configures the processor to obtain preliminary information about a patient via a terminal, store the preliminary information in an EHR, provide the preliminary information to a model trained to predict an emergency medical condition requiring immediate treatment, obtain a likelihood that the patient is suffering from an emergency medical condition from the machine learning model, and provide an alert when the likelihood exceeds a predetermined threshold. In many embodiments, the condition is STEMI, and the preliminary information comprises: age, sex, and at least one chief complaint.

Abstract: Systems and methods for crowdsourced machine learning in accordance with embodiments of the invention are illustrated. In many embodiments, particular crowdworkers from a plurality of crowdworkers who are able to perform with high accuracy and reliability (referred to herein as “super recognizers”) are identified and used to generate training data for machine learning models. In various embodiments, super recognizers are identified by providing a request to answer questions regarding a particular type of input to the plurality of crowdworkers and providing received answers to a machine learning model trained using expert-annotated inputs similar to the inputs provided to the crowdworkers.

Abstract: System, methods, and other embodiments described herein relate to improving the estimation of battery life. In one embodiment, a method includes measuring electrochemical data of a battery cell associated with an electrochemical reaction triggered by a test during a diagnostic cycle. The method also includes determining a feature associated with the degradation of the battery cell from the electrochemical data. The method also includes predicting an end-of-life (EOL) of the battery cell by using the feature in a machine learning (ML) model.